ArticleSmall (Weinheim an der Bergstrasse, Germany)2014
In vivo immune cell distribution of gold nanoparticles in naïve and tumor bearing mice.
Article in Small (Weinheim an der Bergstrasse, Germany), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Steering spherical nucleic acids over metabolic organs for improved targeted drug delivery.Journal of nanobiotechnology · 2026Review
- Gold Nanoparticle Inhibits the Tumor-Associated Macrophage M2 Polarization by Inhibiting mAnalytical cellular pathology (Amsterdam) · 2025Article
- Targeted Lymphoma Therapy Using a Gold Nanoframework-Based Drug Delivery System.ACS applied materials & interfaces · 2023Article
- Nanomaterials-Based Novel Immune Strategies in Clinical Translation for Cancer Therapy.Molecules (Basel, Switzerland) · 2023Review
- Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.International journal of nanomedicine · 2023Review
- Different coatings on magnetic nanoparticles dictate their degradation kinetics in vivo for 15 months after intravenous administration in mice.Journal of nanobiotechnology · 2022Article
- Article
- Absolute Quantification of Nanoparticle Interactions with Individual Human B Cells by Single Cell Mass Spectrometry.Nano letters · 2022Article
- Safety Evaluation of Nanotechnology Products.Pharmaceutics · 2021Review
- Design and Encapsulation of Immunomodulators onto Gold Nanoparticles in Cancer Immunotherapy.International journal of molecular sciences · 2021Review
- Pharmacokinetics, Biodistribution, and Biosafety of PEGylated Gold Nanoparticles In Vivo.Nanomaterials (Basel, Switzerland) · 2021Article
- Current role of nanoparticles in the treatment of lung cancer.Journal of clinical and translational research · 2021Review
- Adaptive changes induced by noble-metal nanostructuresTheranostics · 2020Review
- Gold nanoparticles in chemo-, immuno-, and combined therapy: review [Invited].Biomedical optics express · 2019Article
- Review
- Tannic Acid-Modified Silver and Gold Nanoparticles as Novel Stimulators of Dendritic Cells Activation.Frontiers in immunology · 2018Article
- High-throughput quantitation of inorganic nanoparticle biodistribution at the single-cell level using mass cytometry.Nature communications · 2017Article
- Subtumoral analysis of PRINT nanoparticle distribution reveals targeting variation based on cellular and particle properties.Nanomedicine : nanotechnology, biology, and medicine · 2016Article
- Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors.Journal of controlled release : official journal of the Controlled Release Society · 2015Review
- Stealth filaments: Polymer chain length and conformation affect the in vivo fate of PEGylated potato virus X.Acta biomaterialia · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Gold nanoparticles (AuNP) have been widely used for drug delivery and have recently been explored for applications in cancer immunotherapy. Although AuNPs are known to accumulate heavily in the spleen, the particle distribution within immune cells has not been thoroughly studied. Here, cellular distribution of Cy5 labeled 50 nm AuNPs is characterized within the immune populations of the spleen from naïve and tumor bearing mice using flow cytometry. Surprisingly, approximately 30% of the detected AuNPs are taken up by B cells at 24 h, with about 10% in granulocytes, 18% in dendritic cells, and 8% in T cells. In addition, 3% of the particles are detected within myeloid derived suppressor cells, an immune suppressive population that could be targeted for cancer immunotherapy. Furthermore, it is observed that, over time, the particles traveled from the red pulp and marginal zone to the follicles of the spleen. Taking into consideration that the particle cellular distribution does not change at 1, 6 and 24 h, it is highly suggestive that the immune populations carry the particles and migrate through the spleen instead of the particles migrating through the tissue by cell-cell transfer. Finally, no difference is observed in particle distribution between naïve and tumor bearing mice in the spleen, and nanoparticles are detected within 0.7% of dendritic cells of the tumor microenvironment. Overall, these results can help inform and influence future AuNP delivery design criteria including future applications for nanoparticle-mediated immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.